Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

amneal pharmaceuticals of new york llc - methyltestosterone (unii: v9efu16zif) (methyltestosterone - unii:v9efu16zif) - methyltestosterone 10 mg - androgens are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone: - primary hypogonadism (congenital or acquired) — testicular failure due to cryptorchidism, bilateral torsions, orchitis, vanishing testis syndrome; or orchidectomy. - hypogonadotropic hypogonadism (congenital or acquired) — gonadotropin or luteinizing hormone-releasing hormone (lhrh) deficiency, or pituitary hypothalamic injury from tumors, trauma, or radiation. (appropriate adrenal cortical and thyroid hormone replacement therapy are still necessary, however, and are actually of primary importance.) if the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics. prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty. safety and efficacy of methyltestosterone in men with “ag

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

valeant pharmaceuticals north america llc - methyltestosterone (unii: v9efu16zif) (methyltestosterone - unii:v9efu16zif) - methyltestosterone 10 mg

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

valeant pharmaceuticals north america llc - methyltestosterone (unii: v9efu16zif) (methyltestosterone - unii:v9efu16zif) - methyltestosterone 10 mg

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

endo usa, inc. - testosterone (unii: 3xmk78s47o) (testosterone - unii:3xmk78s47o) - testosterone 75 mg - males androgens are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone. a. primary hypogonadism (congenital or acquired) - testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testes syndrome; or orchiectomy. b. hypogonadotropic hypogonadism (congenital or acquired) - gonadotropic lhrh deficiency, or pituitary - hypothalamic injury from tumors, trauma or radiation. if the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sex characteristics. prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty. safety and efficacy of testopel® (testosterone pellets) in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established. c. androgens may be used to stimulate puberty in carefully selected males with clearly delayed puberty. these patients usually have a familial pattern of delayed puberty that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date. brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. the potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. an x-ray of the hand and wrist to determine bone age should be taken every 6 months to assess the effect of treatment on epiphyseal centers (see warnings). androgens are contraindicated in men with carcinomas of the breast or with known or suspected carcinomas of the prostate. if administered to pregnant women, androgens cause virilization of the external genitalia of the female fetus. the virilization includes clitoromegaly, abnormal vaginal development, and fusion of genital folds to form a scrotal-like structure. the degree of masculinization is related to the amount of drug given and the age of the fetus, and is most likely to occur in the female fetus when the drugs are given in the first trimester. if the patient becomes pregnant while taking these drugs she should be apprised of the potential hazard to the fetus. controlled substance testopel® contains testosterone, a schedule iii controlled substance in the controlled substances act. abuse drug abuse is intentional non-therapeutic use of a drug, even once, for its rewarding psychological and physiological effects. abuse and misuse of testosterone are seen in male and female adults and adolescents. testosterone, often in combination with other anabolic androgenic steroids (aas), and not obtained by prescription through a pharmacy, may be abused by athletes and bodybuilders. there have been reports of misuse of men taking higher doses of legally obtained testosterone than prescribed and continuing testosterone despite adverse events or against medical advice. abuse-related adverse reactions serious adverse reactions have been reported in individuals who abuse anabolic androgenic steroids, and include cardiac arrest, myocardial infarction, hypertrophic cardiomyopathy, congestive heart failure, cerebrovascular accident, hepatotoxicity, and serious psychiatric manifestations, including major depression, mania, paranoia, psychosis, delusions, hallucinations, hostility and aggression. the following adverse reactions have also been reported in men: transient ischemic attacks, convulsions, hypomania, irritability, dyslipidemias, testicular atrophy, subfertility, and infertility. the following additional adverse reactions have been reported in women: hirsutism, virilization, deepening of voice, clitoral enlargement, breast atrophy, male-pattern baldness, and menstrual irregularities. the following adverse reactions have been reported in male and female adolescents: premature closure of bony epiphyses with termination of growth, and precocious puberty. because these reactions are reported voluntarily from a population of uncertain size and may include abuse of other agents, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. dependence behaviors associated with addiction continued abuse of testosterone and other anabolic steroids, leading to addiction is characterized by the following behaviors: - taking greater dosages than prescribed - continued drug use despite medical and social problems due to drug use - spending significant time to obtain the drug when supplies of the drug are interrupted - giving a higher priority to drug use than other obligations - having difficulty in discontinuing the drug despite desires and attempts to do so - experiencing withdrawal symptoms upon abrupt discontinuation of use physical dependence is characterized by withdrawal symptoms after abrupt drug discontinuation or a significant dose reduction of a drug. individuals taking supratherapeutic doses of testosterone may experience withdrawal symptoms lasting for weeks or months which include depressed mood, major depression, fatigue, craving, restlessness, irritability, anorexia, insomnia, decreased libido and hypogonadotropic hypogonadism. drug dependence in individuals using approved doses of testosterone for approved indications has not been documented.

Αρμενία - Αγγλικά - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

handok inc. - glimepiride, metformin (metformin hydrochloride) - tablets film-coated - 2mg+500mg

Αρμενία - Αγγλικά - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

denk pharma gmbh & co. kg - glimepiride - tablets - 3mg

Αρμενία - Αγγλικά - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

denk pharma gmbh & co. kg - glimepiride - tablets - 2mg

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

besins healthcare australia pty ltd - testosterone, quantity: 0.05 g - gel - excipient ingredients: purified water; sodium hydroxide; carbomer 980; ethanol; isopropyl myristate - indicated for use as testosterone replacement therapy for male hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests.

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

slate pharma - testosterone (unii: 3xmk78s47o) (testosterone - unii:3xmk78s47o) - males androgens are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone. if the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sex characteristics. prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty. androgens are contraindicated in men with carcinomas of the breast or with known or suspected carcinomas of the prostate. if administered to pregnant women, androgens cause virilization of the external genitalia of the female fetus. the virilization includes clitoromegaly, abnormal vaginal development, and fusion of genital folds to form a scrotal-like structure. the degree of masculinization is related to the amount of drug given and the age of the fetus, and is most likely to occur in the female fetus when the drugs are given in the first trimester. if

Αρμενία - Αγγλικά - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

handok inc. - glimepiride, metformin (metformin hydrochloride) - tablets prolonged-release - 2mg+ 500mg